4 completed, 4 unknown, 3 terminated, 3 withdrawn. 15 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 4, Unknown 4, Terminated 3, Withdrawn 3, Active not recruiting 1 |
| Phase 1 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Cytokine Storm: new trials by email Literature Review of Cytokine Storm trials Research Report on Cytokine Storm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients MRG-001 (Low-dose), MRG-001 (High-dose), Placebo - Acute Respiratory Distress Syndrome, Respiratory Failure | Phase 2 | Unknown | MedRegen LLC | 60 | 2024-12-01 | 2024-08-23 |
| Anakinra in Dengue With Hyperinflammation ( AnaDen ) Placebo, Anakinra - Dengue, Dengue With Warning Signs | Phase 2 | Active not recruiting | Oxford University Clinical Research Unit, Vietnam | 160 | 2023-01-02 | 2026-01-06 |
| CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 DeltaRex-G - COVID-19, Cytokine Storm | Phase 1 / Phase 2 | Withdrawn | Aveni Foundation | 2022-12-12 | 2025-02-24 | |
| Anakinra, COVID-19, Cytokine Storm Anakinra, 0.9% Saline - Covid19, Cytokine Storm | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2021-12-01 | 2022-01-25 | |
| Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Basiliximab Injection, Placebo - SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection | Phase 2 | Unknown | Fort Worth Clinical Sciences Working Group | 300 | 2021-10-15 | 2021-08-19 |
| Menstrual Blood Stem Cells in Severe Covid-19 Allogeneic human menstrual blood stem cells secretome, Intravenous saline injection - Covid19, Cytokine Storm | Phase 1 / Phase 2 | Completed | Avicenna Research Institute | 29 | 2021-04-17 | 2021-09-02 |
| Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure Copaxone, guideline directed medical therapy (GDMT) - Acute Decompensated Heart Failure, Cytokine Storm | Phase 2 | Completed | Hadassah Medical Organization | 14 | 2021-01-04 | 2023-08-22 |
| Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes esmolol - Sepsis, Lymphocyte Disorder T | Phase 2 | Completed | Lin Chen | 150 | 2021-01-01 | 2024-05-29 |
| Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients Collagen-Polyvinylpyrrolidone - Covid19, Cytokine Storm | Phase 1 / Phase 2 | Unknown | Janette Furuzawa Carballeda | 90 | 2020-08-19 | 2021-02-17 |
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM Doxycycline, Placebo - Cytokine Storm, SARS-CoV-2 | Phase 2 | Withdrawn | Temple University | 2020-06-22 | 2021-04-19 | |
| Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia Injection of Secretome-MSCs, Standard treatment of Covid-19 - Covid-19, Cytokine Storm | Phase 2 | Unknown | Stem Cell and Cancer Research Indonesia | 48 | 2020-06-08 | 2021-05-24 |
| Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 Hyperbaric oxygen - SARS (Severe Acute Respiratory Syndrome), Cytokine Storm | Phase 2 / Phase 3 | Terminated | Karolinska Institutet | 34 | 2020-06-03 | 2023-01-09 |
| A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 SNDX-6352, Placebo - Coronavirus, COVID | Phase 2 | Terminated | Syndax Pharmaceuticals | 1 | 2020-05-30 | 2022-07-22 |
| Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome BAT + Calcifediol, BAT - SARS-CoV 2, COVID19 | Phase 2 | Completed | Maimónides Biomedical Research Institute of Córdoba | 517 | 2020-05-07 | 2023-03-03 |
Cytokine Release Syndrome (15) · COVID-19 (9) · Respiratory Distress Syndrome (4) · Coronavirus Infections (2) · Heart Failure (2) · Respiratory Insufficiency (2) · Severe Acute Respiratory Syndrome (2) · Autonomic Nervous System Diseases (1) · Cardiovascular Diseases (1) · Dengue (1) · Dyspnea (1) · Hypoxia (1) · Macrophage Activation Syndrome (1) · Myocardial Infarction (1) · Pneumonia (1)
Inflammation (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Shock (15) · Systemic Inflammatory Response Syndrome (15) · Infections (12) · RNA Virus Infections (11) · Virus Diseases (11) · Coronaviridae Infections (10) · Lung Diseases (10) · Nidovirales Infections (10) · Pneumonia, Viral (9) · Respiratory Tract Diseases (9) · Respiratory Tract Infections (9) · Coronavirus Infections (8)
Interleukin 1 Receptor Antagonist Protein (2) · Basiliximab (1) · Calcifediol (1) · Doxycycline (1) · Glatiramer Acetate (1) · Hyperbaric Oxygenation (1) · Saline Solution (1) · VIP-ELP fusion molecule PB1046 (1) · axatilimab (1) · collagen-PVP (1) · esmolol (1) · glycine N-choloyltransferase (1) · retrovector encoding mutant anti-cyclin G1 (1)
Aveni Foundation (1) · Avicenna Research Institute (1) · Fort Worth Clinical Sciences Working Group (1) · Hadassah Medical Organization (1) · Janette Furuzawa Carballeda (1) · Karolinska Institutet (1) · Lin Chen (1) · Maimónides Biomedical Research Institute of Córdoba (1) · MedRegen LLC (1) · Oxford University Clinical Research Unit, Vietnam (1) · PhaseBio Pharmaceuticals Inc. (1) · Stem Cell and Cancer Research Indonesia (1) · Syndax Pharmaceuticals (1) · Temple University (1) · Weill Medical College of Cornell University (1)
United States (4) · China (1) · Germany (1) · Indonesia (1) · Iran (1) · Israel (1) · Mexico (1) · Spain (1) · Sweden (1) · Vietnam (1)
Agung Putra, Assoc.Prof (1) · Ali Dehghan-Manshadi, MD (1) · Anders Kjellberg, MD (1) · Arthur M Feldman, MD, PhD (1) · Daniel Azamar-Llamas, MD (1) · Eric Ochoa-Hein, MD (1) · Gonzalo Torres-Villalobos, MD, PhD (1) · Gordon R Bernard, MD (1) · Iris Y Navarro-Millan, MD, MSPH (1) · Janette Furuzawa-Carballeda, PhD (1) · Kenny Rodriguez-Wallberg, MD, PhD (1) · Lin Chen, doctoral (1)
PMID 10415784, PMID 12563677, PMID 14719037, PMID 15663512, PMID 17181919, PMID 18097874, PMID 19397687, PMID 19453649, PMID 19998041, PMID 21131395, PMID 22028728, PMID 22545014, PMID 22731679, PMID 26867177, PMID 28584818, PMID 30473697, PMID 31986264, PMID 32035018, PMID 32089354, PMID 32113509, PMID 32125455, PMID 32159775, PMID 32192578, PMID 32203186, PMID 32234467, PMID 32257537, PMID 32278362, PMID 32283152, PMID 32360286, PMID 32396163, PMID 32747157, PMID 33274176, PMID 34029377, PMID 34226219, PMID 34473343, PMID 35255966, PMID 37510965, PMID 37633275, PMID 38240494, PMID 39393522, PMID 39931105, PMID 40421209, PMID 9804346